| Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer P Tarantino, Q Jin, N Tayob, RM Jeselsohn, SJ Schnitt, J Vincuilla, ... JAMA oncology 8 (8), 1177-1183, 2022 | 119 | 2022 |
| GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis AG Singal, N Tayob, A Mehta, JA Marrero, H El‐Serag, Q Jin, ... Hepatology 75 (3), 541-549, 2022 | 82 | 2022 |
| Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis AG Singal, N Tayob, A Mehta, JA Marrero, Q Jin, J Lau, ND Parikh Clinical Gastroenterology and Hepatology 20 (4), 953-955. e2, 2022 | 25 | 2022 |
| HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications P Tarantino, SM Niman, TK Erick, N Priedigkeit, BT Harrison, A Giordano, ... European Journal of Cancer 174, 277-286, 2022 | 16 | 2022 |
| Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib P Tarantino, Q Jin, EA Mittendorf, TA King, G Curigliano, SM Tolaney Annals of Oncology 33 (8), 845-847, 2022 | 8 | 2022 |
| 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer P Tarantino, Q Jin, N Tayob, R Jeselsohn, SJ Schnitt, J Vincuilla, T Parker, ... Annals of Oncology 33, S124, 2022 | 8 | 2022 |
| Association of physical activity with arterial stiffness among Black adults SJ Islam, N Beydoun, A Mehta, JH Kim, YA Ko, Q Jin, P Baltrus, ML Topel, ... Vascular Medicine 27 (1), 13-20, 2022 | 5 | 2022 |
| Circulating progenitor cells and outcomes in patients with coronary artery disease DS Dhindsa, SR Desai, Q Jin, PB Sandesara, A Mehta, C Liu, AS Tahhan, ... International Journal of Cardiology 373, 7-16, 2023 | 4 | 2023 |
| Axillary nodal response to neoadjuvant T-DM1 combined with pertuzumab in a prospective phase II multi-institution clinical trial A Weiss, Q Jin, AG Waks, D Yardley, LM Spring, E Wrabel, N Tayob, ... Journal of the American College of Surgeons 238 (3), 303-311, 2024 | 2 | 2024 |
| Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer F Hermida-Prado, Y Xie, S Sherman, Z Nagy, D Russo, T Akhshi, Z Chu, ... Cancer Research 83 (19), 3284-3304, 2023 | 2 | 2023 |
| Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic … J Gómez Tejeda Zañudo, R Barroso-Sousa, E Jain, Q Jin, T Li, ... medRxiv, 2022.07. 11.22277416, 2022 | 2 | 2022 |
| Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial J Gómez Tejeda Zañudo, R Barroso-Sousa, E Jain, Q Jin, T Li, ... Nature Communications 15 (1), 2446, 2024 | 1 | 2024 |
| Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer S Morganti, CJ Gibson, Q Jin, K Santos, A Patel, A Wilson, M Merrill, ... Journal of Clinical Oncology, JCO. 23.01071, 2024 | 1 | 2024 |
| 354 GALAD DEMONSTRATES HIGH SENSITIVITY FOR EARLY-STAGE DETECTION OF HEPATOCELLULAR CARCINOMA IN A COHORT OF PATIENTS WITH CIRRHOSIS AG Singal, N Tayob, AJ Fobar, Q Jin, CS de Viteri, JA Marrero, ND Parikh Gastroenterology 160 (6), S-66, 2021 | 1 | 2021 |
| Abstract PO3-03-05: Clinical outcomes in early-stage TNBC according to HER2-low status A Garrido-Castro, DB Zakon, Q Jin, M Grimm, AS Raghavendra, ... Cancer Research 84 (9_Supplement), PO3-03-05-PO3-03-05, 2024 | | 2024 |
| Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer S Morganti, Q Jin, J Vincuilla, R Buehler, S Ryan, S Stokes, T Parker, ... NPJ Breast Cancer 10 (1), 28, 2024 | | 2024 |
| 285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study S Morganti, SE Kim, Q Jin, J Cha, JE Zeigler, AB Newman, J Vincuilla, ... Annals of Oncology 34, S298, 2023 | | 2023 |
| Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance … D Trapani, Q Jin, CC Block, RA Freedman, NU Lin, P Tarantino, ... JCO Oncology Practice 19 (8), 560-570, 2023 | | 2023 |
| Mo1129 PHASE 3 BIOMARKER STUDY FOR HCC SURVEILLANCE USING A NOVEL HES V2. 0 ALGORITHM. A PROSPECTIVE COLLECTION WITH RETROSPECTIVE BLINDED EVALUATION HB El-Serag, N Tayob, Q Jin, A Alsarraj, AG Singal, JA Marrero, SK Asrani, ... Gastroenterology 164 (6), S-767, 2023 | | 2023 |
| Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and … S Morganti, Q Jin, J Vincuilla, R Buehler, S Ryan, S Stokes, T Parker, ... Cancer Research 83 (5_Supplement), P2-01-02-P2-01-02, 2023 | | 2023 |
